nach oben

Drugs & Aging

Erschienen in:

01.02.2000 | New Drug Profile

Extended-Release Oxybutynin

verfasst von: Alison M. Comer, Karen L. Goa

Erschienen in: Drugs & Aging | Ausgabe 2/2000

Einloggen, um Zugang zu erhalten

Abstract

▲ Extended-release oxybutynin (Ditropan XL®¹) uses an osmotic system (OROS®) to deliver a controlled amount of oxybutynin chloride into the gastrointestinal tract over a 24-hour period when taken once daily.
▲ Oxybutynin binds to M3 muscarinic receptors on the detrusor muscle of the bladder, preventing acetylcholinergic activation and relaxing the muscle.
▲ Mean peak plasma concentrations are lower with extended-release oxybutynin 15mg once daily than with conventional immediate-release oxybutynin 5mg taken 3 times daily. Relative bioavailabilities of parent drug and metabolite N-desethoxybutynin are 153 and 69%, respectively, for extended-release oxybutynin when compared with immediate-release oxybutynin.
▲ In short (≤6 weeks) randomised, double-blind clinical trials of patients with detrusor instability, extended-release oxybutynin 5 to 30mg once daily significantly reduced the mean weekly number of urge incontinence episodes by 84 to 90%. Extended-release oxybutynin had similar efficacy to immediate-release oxybutynin.
▲ Adverse events reported by patients taking extended-release oxybutynin were dose-related anticholinergic effects, most frequently dry mouth, somnolence, constipation, blurred vision and dizziness.
▲ A large noncomparative study demonstrated that approximately two thirds of the patients prescribed extended-release oxybutynin for detrusor instability were still taking the medication 6 months later.

Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995 Mar; 6: 243–62PubMedCrossRef

Chutka DS, Fleming KC, Evans MP, et al. Urinary incontinence in the elderly population. Mayo Clin Proc 1996 Jan; 71: 93–101PubMedCrossRef

Chutka DS, Takahashi PY. Urinary incontinence in the elderly: drug treatment options. Drugs 1998 Oct; 56: 587–95PubMedCrossRef

Fantl JA. Behavioural intervention for community-dwelling individuals with urinary incontinence. Urology 1998; 51 Suppl. 2A: 30–4PubMedCrossRef

Wagg A, Malone-Lee J. The management of urinary incontinence in the elderly. Br J Urol 1998 Dec; 82 Suppl. 1: 11–7PubMed

Portera SG, Lipscomb GH. Pharmacologic therapy for urinary incontinence and voiding dysfunctions. Clin Obstet Gynecol 1998 Sep; 41: 691–701PubMedCrossRef

Appell RA. Electrical stimulation for the treatment of urinary incontinence. Urology 1998; 51 Suppl. 2A: 24–6PubMedCrossRef

Appell RA. Surgery for the treatment of overactive bladder. Urology 1998; 51 Suppl. 2A: 27–9PubMedCrossRef

Urinary Incontinence in Adults Guideline Update Panel. Urinary incontinence in adults: acute and chronic management. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1996. AHCPR publication no. 96-0682

10.

Appell R, Chancellor M, editors. Once-a-day Ditropan XL® (oxybutynin chloride) extended-release tablets 5mg and 10mg: product monograph. Palo Alto (CA): ALZA Corporation, 1999

11.

Levin RM, Wein AJ. Direct measurement of the anticholinergic activity of a series of pharmacological compounds on the canine and rabbit urinary bladder. J Urol 1982; 128(2): 396–8PubMed

12.

Smith ER, Wright SE, Aberg G, et al. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline. Arzneimittel Forschung 1998 Oct; 48: 1012–8PubMed

13.

Noronha-Blob L, Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther 1991 Feb; 256: 562–7PubMed

14.

Kachur JF, Peterson JS, Carter JP, et al. R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J Pharmacol Exp Ther 1988 Dec; 247: 867–72PubMed

15.

Tonini M, Rizzi CA, Perucca E, et al. Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle. J Pharm Pharmacol 1987 Feb; 39: 103–7PubMedCrossRef

16.

Yono M, Yoshida M, Takahashi W, et al. Comparison of various antimuscarinic drugs on human detrusor smooth muscles [abstract no. 175]. J Urol 1999 Apr; 161 Suppl.: 48CrossRef

17.

Yamaguchi O, Shishido K, Tamura K, et al. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 1996; 156(3): 1208–13PubMedCrossRef

18.

Moore KH, Hay DM, Imrie AE, et al. Oxybutynin hydrochloride (3mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 1990 Nov; 66: 479–85PubMedCrossRef

19.

Tapp AJS, Cardozo LD, Versi E, et al. The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: a double-blind placebo-controlled study. Br J Obstet Gynaecol 1990 Jun; 97: 521–6PubMedCrossRef

20.

Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999 Mar; 39: 289–96PubMed

21.

Alza Corporation. Ditropan XL® (oxybutynin chloride) extended-release tablets prescribing information. Palo Alto (CA), 1999

22.

Yaich M, Popon M, Medard Y, et al. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-desethyloxy-butynin in humans. Pharmacogenetics 1998 Oct; 8: 449–51PubMedCrossRef

23.

Waldeck K, Larsson B, Andersson K-E. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997 Mar; 157: 1093–7PubMedCrossRef

24.

Paine MF, Khalighi M, Fisher JM, et al. Characterisation of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283(3): 1552–62PubMed

25.

Versi E. Improving urge incontinence treatment by decreasing dry mouth with controlled-release oxybutynin [abstract poster]. Obstet Gynecol 1999 Apr; 93 Suppl.: 78CrossRef

26.

Zinner NR. Patient-oriented outcomes with once-daily oxybutynin for urge incontinence [abstract]. Obstet Gynecol 1999 Apr; 93 Suppl.: 29CrossRef

27.

Anderson RU, Mobley D, Blank B, et al. Once dailycontrolled versus immediate-release oxybutynin chloride for urge urinary incontinence. OROS® Oxybutynin Study Group. J Urol 1999 Jun; 161: 1809–12PubMedCrossRef

28.

Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999 Sep; 54: 420–3PubMedCrossRef

29.

Labasky R, Leach G, Antoci J. Long-term experience with once-a-day extended-release oxybutynin in a communitybased population treated for overactive bladder [abstract]. 29th International Continence Society Meeting; 1999 Aug 22–26; Denver (CO)

30.

Schmidt RA. Efficacy of controlled-release, once-a-day oxybutynin chloride for urge urinary incontinence [abstract no. 188]. 28th International Continence Society Meeting; 1998 Sep 14–17; Jerusalem

31.

Alza Corporation. Analysis of weekly total void frequency: patients randomised to OROS® oxybutynin, IR oxybutynin or oral placebo treatment groups. Study no. 95-031. (Data on file)

32.

Kelleher CJ, Cardozo LD, Khullar V, et al. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low compliance. Br J Obstet Gynaecol 1997; 104: 988–93PubMedCrossRef

33.

Nasr SZ, Ouslander JG. Urinary incontinence in the elderly: causes and treatment options. Drugs Aging 1998 May; 12: 349–60PubMedCrossRef

34.

Chancellor MB, Sathyan G, Gupta SK. Spit study to compare different formulations of oxybutynin [abstract no. 989]. J Urol 1999; 161(4) Suppl.: 256CrossRef

35.

Alza Corporation. Survival analysis of first dry mouth — dose to event. Kaplan-Meier analysis of combined data from studies 95-049 and 97-020. (Data on file)

Titel: Extended-Release Oxybutynin
verfasst von: Alison M. Comer
Karen L. Goa
Publikationsdatum: 01.02.2000
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 2/2000
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200016020-00008

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2000